Identify manufacturing bottlenecks early. Use the tool below to generate a tailored Design for Manufacturability (DFM) checklist based on your catheter's architecture, wall constraints, and clinical application.
A systematic approach ensures that high-risk design features are flagged before costly prototype tooling is ordered.
Statistical yield in volume manufacturing is governed by these physical realities of extrusion, braiding, and thermal processing.
Braid-dominant, coil-dominant, and hybrid shafts fail in different places: braid crossovers can limit jacket wet-out, coils can shift pitch under handling, and hybrid transitions concentrate bending and tensile load.
Action: The checklist must start from the selected reinforcement geometry instead of using one generic catheter-shaft review for every program.
As the radial wall budget narrows, wire profile, liner thickness, jacket flow, and heat-shrink pressure have less process margin. Supplier-quoted sub-0.001 inch wall concepts should be treated as capability claims until proven by coupon builds.
Action: Separate functional tolerances from cosmetic or commercial tolerances before asking a supplier to quote yield and scale-up cost.
In hybrid shafts, a proximal braid-to-distal-coil transition creates a discontinuity in reinforcement density, jacket flow, and bending stiffness. Transfers between machines add handling risk.
Action: Define overlap length, pitch/PPI change limits, hinging limits, and inspection method before ordering tooling.
| Category | Manufacturing Risk | OEM Mitigation Strategy |
|---|---|---|
| Material Variations | Liner thickness variation (PTFE, FEP, HDPE) reducing ID or pushing reinforcement outward. | Define incoming liner-wall, ID, OD, etch-quality, and mandrel tolerance limits before braid or coil application. |
| Reflow Quality | Incomplete polymer wetting leaving voids at wire crossovers (especially high-PPI braids). | Use a tie-layer or lower-viscosity inner jacket layer (e.g. Pebax, TPU); validate reflow time/temp curves with sectioning. |
| Assembly Handling | Coil pitch distortion during loading or jacket application, leading to inconsistent flexibility. | Automated winding with active tension control; handle on mandrels until final jacket is set. Limit manual handling. |
| Regulatory & Sterilization | Material degradation or bonding failure post-sterilization (e.g. Gamma vs. EtO). | Screen material stack candidates against the intended sterilization path and repeat bond, kink, and tensile checks after sterilization exposure. |
Risk: Liner thickness variation (PTFE, FEP, HDPE) reducing ID or pushing reinforcement outward.
Mitigation: Define incoming liner-wall, ID, OD, etch-quality, and mandrel tolerance limits before braid or coil application.
Risk: Incomplete polymer wetting leaving voids at wire crossovers (especially high-PPI braids).
Mitigation: Use a tie-layer or lower-viscosity inner jacket layer (e.g. Pebax, TPU); validate reflow time/temp curves with sectioning.
Risk: Coil pitch distortion during loading or jacket application, leading to inconsistent flexibility.
Mitigation: Automated winding with active tension control; handle on mandrels until final jacket is set. Limit manual handling.
Risk: Material degradation or bonding failure post-sterilization (e.g. Gamma vs. EtO).
Mitigation: Screen material stack candidates against the intended sterilization path and repeat bond, kink, and tensile checks after sterilization exposure.
Updated July 26, 2026. Public regulatory sources frame the quality-system, biocompatibility, and sterilization obligations. The dimensional and process claims on this page are DFM screening assumptions that should be verified with supplier drawings, coupon builds, and process capability data.
Sets the dominant failure mode: braid wet-out and birdcaging, coil pitch control, or hybrid transition integrity.
Verify with: Confirm with sectioning, bend/kink testing, torque response, tensile pull, and transition microscopy.
Acts as a process-margin proxy rather than a guaranteed manufacturable wall dimension.
Verify with: Validate by OD/ID capability study, flat-vs-round wire trial, jacket reflow coupon, and Cpk review.
Shifts the review toward tortuosity, payload, long-length pushability, or large-bore ovalization risks.
Verify with: Tie each checklist output back to user needs, simulated-use fixtures, and design verification acceptance criteria.
QMSR effective February 2, 2026; reviewed July 26, 2026
Frames the need to connect DFM findings to documented quality-system controls and ISO 13485-aligned design/development records.
Boundary: It does not publish braid PPI, coil pitch, or catheter-shaft wall capability data.
eCFR current page reviewed July 26, 2026
Supports the checklist emphasis on design inputs, outputs, verification, validation, reviews, changes, and documented acceptance criteria.
Boundary: Regulatory design-control language is not a substitute for device-specific process validation.
FDA final guidance issued September 2023
Supports early material-stack screening when liners, jackets, adhesives, coatings, or sterilization can affect patient-contact risk.
Boundary: Biocompatibility guidance does not prove mechanical performance or manufacturability.
FDA page includes November 2024 EtO updates; reviewed July 26, 2026
Supports treating EtO, radiation, steam, and alternative sterilization methods as material/process compatibility decisions.
Boundary: Sterilization feasibility must still be validated for the final packaged device and process route.
Use these adjacent pages to move from checklist screening into architecture selection, cost control, and supplier qualification.
Model braid angle, PPI, optical coverage %, and wall stack-up before freezing DFM specifications.
Use after the checklist when architecture tradeoffs still need design-level clarification.
Translate the DFM risks into yield, tooling, inspection, and supplier-cost questions.
Turn the checklist into transfer controls, supplier capability questions, and RFQ evidence.
Align your DFM checklist with the necessary functional testing and cross-section microscopy.
Compare manufacturing partners once the critical DFM risks and evidence gaps are known.
Review the broader OEM manufacturing scope before sending drawings, CTQs, and supplier evidence requests.
Send your selected architecture, wall category, clinical use case, and target drawings to our engineering team. We will review the generated DFM checklist against process capabilities for reliable, scalable manufacturing.